Production of plasminogen activators by human T-cell leukaemia virus-transformed human T cell lines. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Production of plasminogen activators by human T-cell leukaemia virus-transformed human T cell lines.

Br J Cancer. 1985 Jun;51(6):753-9. Unique Identifier : AIDSLINE MED/85226150
Hinuma S; Honda S; Tsukamoto K; Sugamura K; Hinuma Y

Abstract: Six human T cell lines HAMA, KUN, KAN, TCL-Haz, TCL-Ter, and TCL-Mor, which were transformed by a retrovirus, human T-cell leukaemia virus (HTLV), constitutively produced plasminogen activators (PAs) in culture supernatants. The amount of PAs produced varied among the cell lines. The PAs were distinguished by immunochemical analysis between two types: urokinase (UK)-type and non-UK-type. KUN, TCL-Ter, and HAMA mainly produced UK-type PA, whereas the other cell lines produced both types. Thus, HTLV-transformed T cell lines differ in the quality and quantity of the PAs they produce. The PAs in the culture supernatants of each cell line were separated into several mol. w forms on sodium dodecyl sulfate polyacrylamide gel electrophoresis. The results indicate that the same cell line produces PAs of different mol. wt. PA production by these cell lines was affected by treatment with phorbol miristate acetate, concanavalin A, and phytohaemagglutinin; the effects were substantially different in each cell line. The data described here indicate that HTLV-transformed T cell lines constitutively produce PAs which are very heterogeneous in both quality and quantity.
Keywords: Cell Line *Cell Transformation, Viral Concanavalin A/PHARMACOLOGY Electrophoresis, Polyacrylamide Gel Human *HTLV-BLV Viruses Phytohemagglutinins/PHARMACOLOGY Plasminogen Activators/*BIOSYNTHESIS T-Lymphocytes/DRUG EFFECTS/*METABOLISM Tetradecanoylphorbol Acetate/PHARMACOLOGY JOURNAL ARTICLE

KWDcelllineKWDcelltransformation,viralconcanavalina/pharmacologyelectrophoresis,polyacrylamidegelhumanKWDhtlv-blvvirusesphytohemagglutinins/pharmacologyplasminogenactivators/KWDbiosynthesist-lymphocytes/drugeffects/KWDmetabolismtetradecanoylphorbolacetate/pharmacologyjournalarticle
851030
M85A0093

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .